On Dec. 8, 2020, Moderna announced the Swiss Federal Government had increased its confirmed order commitment from 4.5 million to 7.5 million doses of Moderna’s vaccine candidate against COVID-19, mRNA-1273. Swiss vaccine supply was sourced from Moderna’s European production capacity with its strategic manufacturing partner Lonza of Switzerland, and ROVI of Spain for fill-finish services.

Moderna remained on track to be able to start delivery of its COVID-19 vaccine candidate to help protect Swiss citizens following regulatory approval by Swiss health authorities. Moderna could ship its COVID-19 vaccine as soon as December if regulatory approval is granted. The Company had already initiated the rolling review process with Swissmedic and intended to seek Prequalification (PQ) and/or Emergency Use Listing (EUL) with the World Health Organization (WHO).

Swiss vaccine supply will be sourced from Moderna’s European production capacity with its strategic manufacturing partner Lonza of Switzerland, and ROVI of Spain for fill-finish services.